EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Antibody–drug conjugates in hematologic malignancies

Krish Patel, Stephen A Strickland, Hans C Lee iD

Cancer · 01.06.2026 · 132 (S1)

DOI: 10.1002/cncr.70421 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 01.06.2026. Verfasst von Krish Patel und 2 weiteren Autor:innen. Beteiligte Einrichtung: Sarah Cannon Research Institute, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Immunoconjugates, Hematologic Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 111 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody–drug conjugates (ADCs) represent an important therapeutic modality for the treatment of various hematologic malignancies. These include gemtuzumab ozogamicin and inotuzumab ozagamicin for acute leukemias; brentuximab vedotin, polatuzumab vedotin, and loncastuximab tesirine for lymphoid malignancies; and belantamab mafadotin for multiple myeloma. Although ADCs do provide an effective off‐the‐shelf approach to selectively deliver cytotoxic agents by targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen target, linker, or payload that have limited their development. In this review, the clinical development and current role of ADCs in the therapeutic landscape of hematologic malignancies are discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesHematologic NeoplasmsAntineoplastic Agents, ImmunologicalHumansAntibodies, Monoclonal, HumanizedGemtuzumabInotuzumab Ozogamicin

Stichwörter der Autor:innen

antibody–drug conjugateshematologic malignanciesleukemialymphomamultiple myeloma

Substanzen

ImmunoconjugatesAntineoplastic Agents, ImmunologicalAntibodies, Monoclonal, HumanizedGemtuzumabInotuzumab Ozogamicinbelantamab mafodotin

Autor:innen und Institutionen

  • Sarah Cannon Research Institute, Nashville, Tennessee, USA.

ORCID-Profile: Hans C Lee

Zitieren

APA

Patel, K., Strickland, S. A., & Lee, H. C. (2026). Antibody–drug conjugates in hematologic malignancies. Cancer, 132(S1). https://doi.org/10.1002/cncr.70421

Vancouver

Patel K, Strickland SA, Lee HC. Antibody–drug conjugates in hematologic malignancies. Cancer. 2026;132(S1). doi:10.1002/cncr.70421

BibTeX
@article{Patel2026,
  author = {Patel, Krish and Strickland, Stephen A and Lee, Hans C},
  title = {Antibody–drug conjugates in hematologic malignancies},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {S1},
  doi = {10.1002/cncr.70421}
}
Kostenlos starten →